Granules India Limited, enters into a strategic partnership with Greenko ZeroC to collaborate for green molecule solutions and its wider applications in pharmaceuticals to build a leadership position in sustainability and circular economy...
BDR Pharmaceutical has launched the first generic Apalutamide (Brand name Apatide) in India to treat metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). ..
Zydus Lifesciences Ltd said it has received final approval from the US health regulator to market its generic version of Triazolam tablets used on a short-term basis to treat insomnia. The approval granted by the US Food and Drug Administration...
The government said it has signed a pact with the Pune-based Institute of Veterinary Biological Products (IVBP) for commercial production of indigenously developed vaccine 'Lumpi-ProVac' for the control of lumpy skin disease in cattle...
Cipla said that its wholly owned UK subsidiary has signed definitive agreements for equity investment of EUR 15 million in Ethris, a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation...
In this article we have combined four promising trends in SUT that is expected to have a lasting impact on the pharmaceutical industry.
India is likely to get an Omicron-specific booster shot soon. Gennova Biopharmaceuticals, subsidiary of Pune-based drug maker Emcure, will soon submit data of clinical trials conducted on its mRNA vaccine that will target the Omicron variant of...
Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received...
Bharat Biotech today announced that iNCOVACC (BBV154), will be rolled out in the fourth week of January as booster dose for those above 18 years of age in India. The intranasal vaccine which is now available on CoWin, has been priced at Rs 800 for...
Pharmaceuticals firm Hetero on Monday said it has received World Health Organisation Prequalification of medicines program (WHO PQ) approval for its generic version of COVID-19 oral antiviral treatment candidate 'Nirmatrelvir'. Hetero's 'NIRMACOM'...
, CDSCO.jpg)
